Rilotumumab Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung

Rilotumumab is an anti-HGF antibody that prevents ligand binding to MET and its activation.

Clinical Use

A phase I/II trial of rilotumumab in combination with erlotinib was evaluated in previously treated NSCLC patients with metastatic disease. The results indicated a favorable safety profile and success in terms of disease control rate. A phase Ib/II trial of rilotumumab or ganitumab in combination with etoposide and carboplatin or cisplatin was evaluated in extensive-stage SCLC patients.

Rilotumumab Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte

Rilotumumab Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.

Firmenname	Telefon	E-Mail	Land	Produktkatalog	Edge Rate
TargetMol Chemicals Inc.	+1-781-999-5354 +1-00000000000	marketing@targetmol.com	United States	32161	58
Aladdin Scientific	+1-+1(833)-552-7181	sales@aladdinsci.com	United States	57505	58
ShangHai Biochempartner Co.,Ltd	17754423994 17754423994	2853530910@QQ.com	China	8011	62
Guangzhou Hongyuan Chemical Co.,Ltd	15817493340	981810490@qq.com	China	1566	58
Wuhan Chemstan Biotechnology Co., Ltd.	027-65317797 15926423062	422450190@qq.com	China	10436	58
TargetMol Chemicals Inc.	4008200310	marketing@tsbiochem.com	China	24644	58
Biolab Reagents	027-65279366 18108604862	products@biolabreagent.com	China	9818	58
Wuhan Jingkangen Biomedical Technology Co., Ltd	13720134139 13720134139	orders@jknbiochem.com	China	5821	58
Shanghai Yifei Biotechnology Co. , Ltd.	021-65675885 18964387627	customer_service@efebio.com	China	11974	58
Shanghai?Medlife?Pharm-Tech?Co.,?Ltd	021-59167510 18117107507	vip@med-life.cn	China	4997	58

---

• Rilotumumab
• Research Grade Rilotumumab(DHD03702)
• Rilotumumab (anti-HGF)
• AMG 102
• 872514-65-3